Every material Form 8-K OnKure Therapeutics, Inc. has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
OnKure Therapeutics reported third quarter 2026 results with a net loss of $17.8 million, or $0.36 per share, compared with $14.7 million, or $1.09 per share, a year earlier. The dollar loss grew as research and development and general and administrative expenses rose, while the per-share loss narrowed on a much larger weighted share count of 49.9 million versus 13.5 million. The company reported $163.3 million in cash, cash equivalents and marketable securities as of September 30, 2026, and said this is expected to fund operations into 2029.
Q3 2026 net loss was $17.8 million ($0.36 per share), up from $14.7 million ($1.09 per share) in Q3 2025
R&D expenses were $15.1 million, up from $11.9 million; G&A expenses were $4.3 million, up from $3.6 million
Cash, cash equivalents and marketable securities were $163.3 million at September 30, 2026, expected to provide runway into 2029
IND submissions for OKI-355 (vascular anomalies) and OKI-345 (breast cancer) are planned for the first half of 2027
On August 7, 2026, OnKure Therapeutics' board approved a repricing of employee and consultant stock options with exercise prices of $10.00 or more, including options held by its named executive officers. The repriced options now carry a $4.14 exercise price, the August 7 closing price, and the filing says the company made no change to expiration dates, vesting or share counts; it states the change was meant to retain staff without new equity grants or added cash pay.
Effective date of August 7, 2026; new exercise price of $4.14 per share, the closing price that day
About 1.7 million shares underlie repriced options, roughly 40% of outstanding options had exercise prices above the $10.00 threshold
CEO Nicholas A. Saccomano holds 571,423 repriced option shares; CMO Samuel Agresta holds 149,984; CFO Jason Leverone holds 141,714
Optionees must stay in service 18 months (senior management, including named executive officers) or one year (other staff), or pay the original higher exercise price
OnKure Therapeutics reported a second-quarter 2026 net loss of $15.3 million, or $0.31 per share, compared with $15.4 million, or $1.14 per share, a year earlier. Weighted average shares rose to 49,869,177 from 13,509,080, which accounts for most of the lower per-share loss. The company said its $176.4 million in cash, cash equivalents and marketable securities is expected to fund operations into 2029.
Q2 2026 net loss of $15.3 million vs. $15.4 million in Q2 2025; loss per share of $0.31 vs. $1.14
R&D expenses of $12.6 million, flat year over year; G&A expenses rose to $4.3 million from $3.7 million
Cash, cash equivalents and marketable securities of $176.4 million as of June 30, 2026, up from $59.1 million at December 31, 2025
IND submissions for OKI-355 and OKI-345 planned for the first half of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every OnKure Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →